search
Back to results

The Pediatric ALL Evaluation and Trial (PALLET)

Primary Purpose

ACL Injury, ACL Tear

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.
Sponsored by
Ann & Robert H Lurie Children's Hospital of Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ACL Injury

Eligibility Criteria

undefined - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 18 and under
  • Surgery within 6 months of injury
  • Undergoing primary ACL reconstruction without previous injury or surgery
  • Autograft ACL reconstruction
  • Closing or closed physes

Exclusion Criteria:

  • Over 18 years old
  • Previous ipsilateral knee injury or surgery
  • Neuromuscular or developmental disorders affecting knee anatomy, cognition, or neuromuscular control
  • Other concomitant ligament reconstruction aside from the ALL (i.e., MCL, PCL, PLC)
  • Revision ACL reconstruction
  • Allograft ACL reconstruction
  • IT band (modified MacIntosh) ACL reconstruction
  • A cartilage lesion requiring anything more than debridement
  • Open physes requiring both femoral and tibial physeal-sparing technique

Sites / Locations

  • Lurie Children's HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Concomitant ACL and ALL reconstruction

ACL reconstruction alone

Arm Description

The participant will undergo both the ACL and ALL reconstruction surgery.

The participant will undergo only ACL reconstruction surgery.

Outcomes

Primary Outcome Measures

Graft failure
To determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure (confirmed graft re-tear or asymmetric, increased pivot shift) than ACL reconstruction alone.

Secondary Outcome Measures

Complications of ALL reconstruction
To determine the rate and severity of complications related specifically to ALL reconstruction in children.
Patient reported outcome measures
To collect and compare patient reported outcome (PRO) scores (as measured by the Pedi-IKDC, Lysholm, HSS Pedi-FABS, and PROMIS surveys) in children undergoing ACL reconstruction alone, and children undergoing combined ACL and ALL reconstruction.

Full Information

First Posted
March 29, 2021
Last Updated
September 1, 2023
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators
Children's Hospital of Philadelphia, Texas Children's, UCSF Benioff Children's Hospital - San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT04825587
Brief Title
The Pediatric ALL Evaluation and Trial
Acronym
PALLET
Official Title
The Pediatric ALL Evaluation and Trial: A Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 28, 2021 (Actual)
Primary Completion Date
April 1, 2026 (Anticipated)
Study Completion Date
April 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators
Children's Hospital of Philadelphia, Texas Children's, UCSF Benioff Children's Hospital - San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The overall aim of this multicenter RCT is to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
Detailed Description
Studies have reported a rising incidence of anterior cruciate ligament (ACL) injuries in children and adolescents. Beck et al reported a 2.3% annual increase between 1994 and 2013. In New York State, the rate of pediatric ACL reconstruction climbed from 17.6/100,000 in 1990 to 50.9/100,000 by 2009. Other reports echo these findings. After ACL reconstruction, children are known to be at a higher risk for complications than adults. For example, while the rate of postoperative graft failure in adults was 3% to 4% in large national registries, as many as 12% to 19% of pediatric patients may sustain graft rupture. This can have substantial medical, financial, and psychosocial implications on the patient and family. Additionally, the results of revision ACL reconstruction are, on average, worse than after index surgery. Exploration of treatments that may lower the rate of re-injury is paramount in this population that is at highest risk. In the adult population, a growing number of studies have suggested that concomitant reconstruction of the anterolateral ligament (ALL) with the ACL may help lower this risk. The ALL was likely first characterized in 1879 by the French surgeon Segond, who commented on the presence of a "pearly, resistant, fibrous band" in the lateral aspect of the knee. However, only in 2012 was the structure given the name "anterolateral ligament" after it was consistently identified in cadaveric specimens. Some studies suggest that the ALL is damaged during anterior cruciate ligament (ACL) injury, implying that it may supplement the ACL in providing rotational and translational stability. Biomechanical studies have confirmed that it likely plays a role in rotational stability. A number of ALL reconstruction techniques have been developed with the hope of lowering the rate of re-injury after ACL reconstruction. Early literature in the adult population suggests that this may indeed be the case. Early case series suggested that concomitant ALL reconstruction resulted in high rates of return to sport and a low ACL graft failure rate (2.6%). Comparative retrospective studies in adults suggest better patient reported outcome scores, meniscal repair healing, and rates of return to sports when the ALL is reconstructed with the ACL compared to isolated ACL reconstruction. Finally, a prospective cohort study of adults reported that hamstring autograft ACL reconstruction with concomitant ALL reconstruction resulted in 3.1 times lower odds of graft failure than isolated hamstring ACL reconstruction and 2.5 times lower odds of failure than isolated patellar tendon ACL reconstruction. The hypotheses to be tested in this study have never been evaluated in the pediatric population. Furthermore, the proposed investigation is a randomized controlled trial, which will allow it to provide novel results with high-level evidence. The results of such a study have the potential to change practice in a meaningful, tangible way and affect the outcomes of thousands of children annually. In addition to the medical and functional impact, there could also be important financial and psychosocial implications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ACL Injury, ACL Tear

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The overall aim of this multicenter RCT is to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will result in a lower rate of graft failure than ACL reconstruction alone.
Masking
Participant
Allocation
Randomized
Enrollment
720 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Concomitant ACL and ALL reconstruction
Arm Type
Experimental
Arm Description
The participant will undergo both the ACL and ALL reconstruction surgery.
Arm Title
ACL reconstruction alone
Arm Type
Experimental
Arm Description
The participant will undergo only ACL reconstruction surgery.
Intervention Type
Procedure
Intervention Name(s)
Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.
Intervention Description
By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
Primary Outcome Measure Information:
Title
Graft failure
Description
To determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure (confirmed graft re-tear or asymmetric, increased pivot shift) than ACL reconstruction alone.
Time Frame
Complete when all 780 participants have been recruited, received an intervention and have been followed for data collection for up to 5 years.
Secondary Outcome Measure Information:
Title
Complications of ALL reconstruction
Description
To determine the rate and severity of complications related specifically to ALL reconstruction in children.
Time Frame
Complete when all 780 participants have been recruited, received an intervention and have been followed for data collection for up to 5 years.
Title
Patient reported outcome measures
Description
To collect and compare patient reported outcome (PRO) scores (as measured by the Pedi-IKDC, Lysholm, HSS Pedi-FABS, and PROMIS surveys) in children undergoing ACL reconstruction alone, and children undergoing combined ACL and ALL reconstruction.
Time Frame
Complete when all 780 participants have been recruited, received an intervention and have been followed for data collection for up to 5 years.

10. Eligibility

Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18 and under Surgery within 6 months of injury Undergoing primary ACL reconstruction without previous injury or surgery Autograft ACL reconstruction Closing or closed physes Exclusion Criteria: Over 18 years old Previous ipsilateral knee injury or surgery Neuromuscular or developmental disorders affecting knee anatomy, cognition, or neuromuscular control Other concomitant ligament reconstruction aside from the ALL (i.e., MCL, PCL, PLC) Revision ACL reconstruction Allograft ACL reconstruction IT band (modified MacIntosh) ACL reconstruction A cartilage lesion requiring anything more than debridement Open physes requiring both femoral and tibial physeal-sparing technique
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lauren Spirov, MS
Phone
312-227-8427
Email
lspirov@luriechildrens.org
First Name & Middle Initial & Last Name or Official Title & Degree
Neeraj Patel, MD
Phone
312-227-6190
Email
neepatel@luriechildrens.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neeraj Patel, MD
Organizational Affiliation
Lurie Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lurie Children's Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren Spirov
Phone
312-227-8427
Email
lspirov@luriechildrens.org
First Name & Middle Initial & Last Name & Degree
Neeraj Patel, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Collected Participant info that may be collected and shared :Personal and health information, Past/present medical records, Records from study visits/phone calls. Behavioral or mental health info about the participants will be collected and may be shared.The study staff, employees, and Medical Staff of Lurie Children's may use participant's info for this study and share it with study sponsor, POSNA and those working with the sponsor, IRB, Participant's other providers and their staff directly involved in their care, if their provider is a part of the Lurie Children's electronic health information exchange: The Office of Human Research Protections (OHRP), the Food and Drug Administration (FDA), or other government offices. We cannot guarantee that those listed above will not share it with others without participant's permission. Participant's names will not be included in any written or verbal reports of study results.
IPD Sharing Time Frame
from the study start up/participant recruitment (beginning April 2021) until 1/1/2030
IPD Sharing Access Criteria
Study personnel only

Learn more about this trial

The Pediatric ALL Evaluation and Trial

We'll reach out to this number within 24 hrs